GlobeNewswire

Cisco 2018 Annual Cybersecurity Report Reveals Security Leaders Rely on and Invest in Automation, Machine Learning and Artificial Intelligence to Defend Against Threats

Dela

Findings show 39 percent of organizations are reliant on automation, 34 percent are reliant on machine learning, 32 percent are highly reliant on AI

SAN JOSE, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Malware sophistication is increasing as adversaries begin to weaponize cloud services and evade detection through encryption, used as a tool to conceal command-and-control activity. To reduce adversaries' time to operate, security professionals said they will increasingly leverage and spend more on tools that use AI and machine learning, reported in the 11th Cisco® 2018 Annual Cybersecurity Report (ACR).

While encryption is meant to enhance security, the expanded volume of encrypted web traffic (50 percent as of October 2017) - both legitimate and malicious - has created more challenges for defenders trying to identify and monitor potential threats. Cisco threat researchers observed more than a threefold increase in encrypted network communication used by inspected malware samples over a 12-month period.

Applying machine learning can help enhance network security defenses and, over time, "learn" how to automatically detect unusual patterns in encrypted web traffic, cloud, and IoT environments. Some of the 3,600 chief information security officers (CISOs) interviewed for the Cisco 2018 Security Capabilities Benchmark Study report, stated they were reliant and eager to add tools like machine learning and AI, but were frustrated by the number of false positives such systems generate. While still in its infancy, machine learning and AI technologies over time will mature and learn what is "normal" activity in the network environments they are monitoring.

"Last year's evolution of malware demonstrates that our adversaries continue to learn," said John N. Stewart, Senior Vice President and Chief Security and Trust Officer, Cisco. "We have to raise the bar now - top down leadership, business led, technology investments, and practice effective security - there is too much risk, and it is up to us to reduce it."

Cisco 2018 Annual Cybersecurity Report Additional Highlights

  • The financial cost of attacks is no longer a hypothetical number:
    • According to study respondents, more than half of all attacks resulted in financial damages of more than US$500,000, including, but not limited to, lost revenue, customers, opportunities, and out-of-pocket costs
       
  • Supply chain attacks are increasing in velocity, complexity
    These attacks can impact computers on a massive scale and can persist for months or even years. Defenders should be aware of the potential risk of using software or hardware from organizations that do not appear to have a responsible security posture.
    • Two such attacks in 2017, Nyetya and Ccleaner, infected users by attacking trusted software.
    • Defenders should review third-party efficacy testing of security technologies to help reduce the risk of supply chain attacks. 
  • Security is  getting more complex, scope of breaches is expanding
    Defenders are implementing a complex mix of products from a cross-section of vendors to protect against breaches. This complexity and growth in breaches has many downstream effects on an organization's ability to defend against attacks, such as increased risk of losses.
    • In 2017, 25 percent of security professionals said they used products from 11 to 20 vendors, compared with 18 percent of security professionals in 2016.
    • Security professionals said 32 percent of breaches affected more than half of their systems, compared with 15 percent in 2016.
  • Security professionals see value in behavioral analytics tools in locating malicious actors in networks
    • 92 percent of security professionals said behavior analytics tools work well. Two-thirds of the healthcare sector, followed by financial services, found behavior analytics to work extremely well to identify malicious actors.
       
  • Use of cloud is growing; attackers taking advantage of the lack of advanced security
    • In this year's study, 27 percent of security professionals said they are using off-premises private clouds, compared with 20 percent in 2016
    • Among them, 57 percent said they host networks in the cloud because of better data security; 48 percent, because of scalability; and 46 percent, because of ease of use.
    • While cloud offers better data security, attackers are taking advantage of the fact that security teams are having difficulty defending evolving and expanding cloud environments. The combination of best practices, advanced security technologies like machine learning, and first-line-of-defense tools like cloud security platforms can help protect this environment.
       
  • Trends in malware volume have an impact on defenders' time to detection (TTD)
    • The Cisco median TTD of about 4.6 hours for the period from November 2016 to October 2017 - well below the 39-hour median TTD reported in November 2015, and the 14-hour median reported in the Cisco 2017 Annual Cybersecurity Report for the period from November 2015 to October 2016.
    • The use of cloud-based security technology has been a key factor in helping Cisco to drive and keep its median TTD to a low level. Faster TTD helps defenders move sooner to resolving breaches.

Additional Recommendations for Defenders:

  • Confirm that they adhere to corporate policies and practices for application, system, and appliance patching.
  • Access timely, accurate threat intelligence data and processes that allow for that data to be incorporated into security monitoring.
  • Perform deeper and more advanced analytics.
  • Back up data often and test restoration procedures, processes that are critical in a world of fast-moving, network-based ransomware worms and destructive cyber weapons.
  • Conduct security scanning of microservice, cloud service, and application administration systems.

About the Report:
The Cisco 2018 Annual Cybersecurity Report, now in its 11th year, highlights findings and insights derived from threat intelligence and cybersecurity trends observed over the past 12-18 months from threat researches and six technology partners: Anomali, Lumeta, Qualys, Radware, SAINT, and TrapX. Also, included in the report are results of the annual Security Capabilities Benchmark Study (SCBS), which this year surveyed 3,600 chief security officers (CSOs) and security operations (SecOps) managers from 26 countries about the state of cybersecurity in their organizations.

Supporting Resources
Cisco 2018 Annual Cybersecurity Report
Cisco Blog: Setting the Cybersecurity Bar Higher - Announcing the Cisco 2018 Annual Cybersecurity
Cisco 2018 Annual Cybersecurity Report Graphics
In-Security video
Follow Cisco Security on Twitter @CiscoSecurity
Follow Cisco Security on LinkedIn 
Follow Cisco Security on Instagram
Like Cisco Security on Facebook

RSS Feed for Cisco:  http://newsroom.cisco.com/dlls/rss.html

About Cisco

Cisco (NASDAQ:CSCO) is the worldwide technology leader that has been making the Internet work since 1984. Our people, products, and partners help society securely connect and seize tomorrow's digital opportunity today. Discover more at newsroom.cisco.com and follow us on Twitter at @Cisco.

Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.

Press Relations
Raquel Prieto
408-527-3754
raqpriet@cisco.com

Analyst Relations
Jenna Duston
408-424-7210
jeabeyta@cisco.com

Investor Relations
Marty Palka 
408-526-6635
mpalka@cisco.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cisco via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum